Haemonetics Launches New Vascade MVP XL Mid-bore Venous Closure Device
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
Haemonetics Launches VASCADE MVP XL Device for Venous Closure
Express News | Haemonetics Launches Limited Market Release for New Vascade Mvp Xl Vascular Closure Device
Haemonetics Corporation's (NYSE:HAE) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Haemonetics' (NYSE:HAE) recent performance, when its stock has declined 12% over the past month. However, a closer look at its sound financials might cause
Haemonetics (HAE) Is a Top-Ranked Value Stock: Should You Buy?
Zacks.com Featured Highlights Include Skechers, Walmart, Haemonetics, AZZ and BOK Financial
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?
Buy 5 Stocks With Upgraded Broker Ratings for Robust Returns
Haemonetics Shares Rise After Upgrade From Needham
Haemonetics (HAE) shares were up 3.5% in recent Wednesday trading after Needham upgraded the stock to buy from hold with a price target of $112. Trading volume stood at about 768,000 shares against a
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112.The analyst says that Haemonetics has reaffirmed its "high-20%" FY26 operatin
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Needham Upgrades Haemonetics(HAE.US) to Buy Rating, Announces Target Price $112
Needham analyst Michael Matson upgrades $Haemonetics(HAE.US)$ to a buy rating, and sets the target price at $112.According to TipRanks data, the analyst has a success rate of 43.4% and a total average
Needham Upgrades Haemonetics to Buy, Announces $112 Price Target
Needham analyst Mike Matson upgrades Haemonetics from Hold to Buy and announces $112 price target.
Haemonetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/12/2024 34.28% Needham → $112 Upgrades Hold → Buy 05/10/2024 49.86% JMP Securities $115 → $125 Maintain
Express News | Haemonetics Corp : Needham Raises to Buy From Hold
Insider Sale: President of Global Hospital at Haemonetics Corp (HAE) Sells Shares
Insider Sale: EVP and General Counsel Michelle Basil Sells 12,990 Shares of Haemonetics Corp (HAE)
Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing
Stewart W Strong, President, Global Hospital, on May 28, 2024, sold 8,857 shares in Haemonetics (HAE) for $775,253. Following the Form 4 filing with the SEC, Strong has control over a total of 18,196